
As the bioequivalence testing market grows, regulators are refining how comparability is demonstrated, making early planning essential for generic and reformulated products.
Bioequivalence (BE) testing has long been used within industry to determine whether two pharmaceutical products containing the same active ingredient can be considered as having comparable in vivo performance. Such comparability is important for developers looking to gain approval for generic versions of originator products or for various formulation and manufacturing changes, and to ensure safety and efficacy for the end user.
In light of upcoming patent expirations, rising healthcare and R&D costs, and the expansion of emerging markets, it is unsurprising that the BE testing market is expected to grow by a compound annual rate of 7.49% over the next few years, reaching a potential value of USD 1.25 billion by 2030 (1). However, as more complex formulation designs and delivery routes are considered by developers, the interpretation and application of BE regulatory standards are having to change.
Regulatory Modernization and Global Harmonization
To keep pace with development advances, regulatory agencies are refining how BE is established. Earlier this year, the U.S. FDA finalized two critical guidance documents for industry focused on establishing BE. These documents provide developers with clearer statistical approaches and pharmacokinetic study frameworks for BE testing, particularly addressing narrow therapeutic index (NTI) drugs and highly variable compounds (2,3).
Simultaneously, international efforts are driving toward unified standards. The European Medicines Agency (EMA) has rolled out important considerations regarding the implementation of the International Council for Harmonization (ICH) M13B guideline, focusing on bioequivalence for immediate-release solid oral dosage forms (4). Ultimately, the ICH M13 series (ICH M13A, M13B, and M13C), which describe the scientific and technical aspects of study design and data analysis in support of BE assessment of orally administered immediate-release solid oral dosage forms, will replace the previous EMA guideline on the investigation of BE.
While these revisions represent a significant stride forward toward harmonization of BE assessment, more work is still required regarding alignment with the most recent scientific progress and digital innovations. As alluded to by Nocera et al., the use of computational methods, such as physiologically based pharmacokinetic modeling and in silico systems, need to be researched further (5).
Facility Compliance and Commercial Stakes
Beyond guidance documents, operational execution is facing greater scrutiny. This scrutiny was underscored when Alembic Pharmaceuticals was issued a formal warning letter by the FDA in July 2026 as a result of failing to properly seek or document informed consent for an in vivo BE study of an investigational drug under 21 CFR parts 312 and 50 (6). However, the company has since successfully cleared an unannounced FDA inspection at the Vadodara bioequivalence facility with zero observations (nil Form 483s) (7).
The stakes for companies are not only about facility and operational compliance but also about potential commercial impact. For emerging biotech innovators, clinical progression can sometimes be too lengthy and lead to a loss of exclusivity, which may prompt reformulations and, hence, further BE studies. For example, Reviva Pharmaceuticals is, at the time of writing, awaiting regulatory feedback on its new formulation of brilaroxazine (developed to extend its patent life), where BE and pharmacokinetic bridging studies will directly dictate clinical progression and commercial viability (8).
Taken together, these developments show that regulatory, operational, and commercial pressures on BE testing are converging. As guidance becomes more harmonized and inspections more rigorous, lapses in study conduct or delays in demonstrating BE can prove costly, whether through regulatory action or lost exclusivity. Building BE considerations into development strategies early, while keeping pace with evolving guidance and emerging tools such as computational modeling, will therefore be key for developers looking to bring generic and reformulated products to market efficiently.
References
1. Research and Markets. Bioequivalence Studies Market — Forecasts from 2025 to 2030. Market Research Report, January 2025.
2. FDA. Statistical Approaches to Establishing Bioequivalence. Final Guidance Document, May 2026.
3. FDA. Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application. Final Guidance Document, May 2026.
4. EMA. Considerations Regarding the Implementation of ICH M13B on Bioequivalence for Immediate-Release Solid Oral Dosage Forms. Scientific Guideline, Oct. 15, 2026.
5. Nocera, D.; Forastiero, G.; Proietti, A.; et al. Toward the Harmonization of Bioequivalence Guidelines in Europe: Commentary on the State of the Art and Future Priorities Under ICH M13A for Immediate-Release Oral Forms. Br. J. Clin. Pharmacol. 2025, 1–5.
6. FDA. Pratik Doshi, M.D./Alembic Pharmaceuticals Ltd. Warning Letter, July 10, 2026.
7. Press Trust of India. Alembic Pharma Clears USFDA Inspection at Vadodara Bioequivalence Facility. Business Standard, Sept. 11, 2026.
8. Reviva Pharmaceuticals. Reviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights. Press Release, Nov. 13, 2026.










